One step further was taken by Cooper et al. [147], who described a strategy for the treatment of r/r T-ALL and non-Hodgkin’s T-cell lymphoma based on a third-generation (CD28 and 4-1BB costimulatory domains) CD7-specific uCAR. This evidence concerns the gene CD7 and acute lymphoblastic leukemia.